|Articles|September 12, 2022
Why eConsent Primes Studies & Patients for Success
Author(s)Medable
According to a survey conducted by Florence Healthcare, 47% of research sites had adopted eConsent by December 2020, just 8 months after the WHO declared an official pandemic. By July 2021, 75% of research sites had either used it or were looking into it. In conclusion - a decentralized consent process is here to stay. Learn why Medable's Total eConsent offering is the industry-leading remote consent technology, and how it can reduce your enrolment timelines by 50%.
Related Content
Trending on PharmExec
1
FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
2
The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels
3
The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026
4
Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration
5